Responses
Regular and young investigator award abstracts
Combination immunotherapies
473 Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro
Compose a Response to This Article
Other responses
No responses have been published for this article.
